Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Symbollon plans pivotal IoGen trial for fibrocystic breast disease

Feb. 17, 2004

Novel oxytocin antagonists and their use as tocolytics reported by ARS team

Feb. 17, 2004

Vivus to develop Testosterone MDTS, Estradiol MDTS for U.S.

Feb. 17, 2004

University of Pennsylvania studies chromium picolinate for metabolic syndrome

Feb. 17, 2004

Full clinical results reported for eculizumab in paroxysmal nocturnal hemoglobinuria

Feb. 17, 2004

Tularik advances T-71 into phase I

Feb. 16, 2004

Novo Nordisk claims novel glucagon receptor inhibitors and their use

Feb. 16, 2004

New antiobesity MCH antagonists developed by Schering-Plough researchers

Feb. 16, 2004

Estrogel receives FDA approval

Feb. 16, 2004

Preliminary analysis of phase I Oxycyte study

Feb. 16, 2004

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 29, 2026.
ENCALS 2026: From genetics to advancing strategies against ALS
BioWorld Science
Amyotrophic lateral sclerosis (ALS)-associated genes provide direct therapeutic targets and reveal pathways that can be used to develop treatments that counteract...
Next wave of BCI firms builds on pioneers to tackle challenges
BioWorld
With the pace of neurotechnology development accelerating, a wave of brain-computer interface (BCI) companies is emerging on the heels of the pioneers. In the...
Elixirgen and Nippon Shinyaku sign EXG-7001 option agreement
BioWorld Science
Elixirgen Therapeutics Inc. has entered into an option agreement with Nippon Shinyaku Co. Ltd. for the development and commercialization of EXG-7001 for Duchenne...
Investors bet on transformative BCI tech for neuro disorders
BioWorld
An estimated $2 billion has been invested in the brain-computer interface (BCI) space in the last two years and the level of funding is expected to continue....